- Supported exchanges /
- ST /
- ABLI.ST
Abliva AB (ABLI ST) stock market data APIs
Abliva AB (publ) discovers and develops medicines for the treatment of mitochondrial disease in Sweden. The company is developing KL1333 that is in Phase 2 clinical trial to treat chronic fatigue and myopathy in genetically confirmed adult patients with primary mitochondrial disease; and NV354, which has completed preclinical development for the treatment of mitochondrial disease with neurologic complications. It has a licensing and collaboration agreement with Owl Therapeutics for NeuroSTAT for the treatment of traumatic brain injury; and Yungjin Pharm on the clinical development of the KL1333, as well as Isomerase, Children's Hospital of Philadelphia, Newcastle University and University College London, and Oroboros Instruments. The company was formerly known as NeuroVive Pharmaceutical AB (publ) and changed its name to Abliva AB (publ) in May 2020. Abliva AB (publ) was incorporated in 2000 and is headquartered in Lund, Sweden.
Abliva AB Financial Data Overview
| -0.175 | |
| -0.2024 | |
| - | |
| -0.125 | |
| -0.114 | |
| 0.1136-0.34 | |
| 213 M | |
| 1 612 M | |
| 137 K | |
| 1.264 |
No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.
Abliva AB Fundamental Data is available in our Financial Data APIs
- Net Revenue 137 K
- EBITDA -91 932 000
- Earnings Per Share -0.09
- Income Statements
- Balance Sheets
- Cash flows
of Fundamental API Data
Get Abliva AB Earnings via APIs
- Latest Release 2024-11-21
- EPS/Forecast NaN
Get Abliva AB End-of-day Data via APIs
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Our 24/7 support would be happy to assist you via chat or email:
support@eodhistoricaldata.comVisit also:
